| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Dandelion root (Taraxacum officinale) -Various phytochemicals, including flavonoids and phenolic compounds, which have antioxidant properties. -Root extract can induce apoptosis -Anti-inflammatory properties -Immune System Support Dosage: dried root 2-8g/d. Extract 250-500mg/d Tea 1-2g, 1-3x/d aqueous Dandelion flower extracts (DFE), dandelion leaf extract (DLE), and dandelion root extract (DRE) may have different effects. Common Names: Blowball, Puffball, Lion's tooth, Pu gong ying, Swine snout, Wild endive Taraxacum officinale is rich in flavonoids (e.g., luteolin, quercetin glycosides), phenolic acids (chicoric, chlorogenic, and caffeic acids), terpenoids (taraxasterol, taraxerol), sesquiterpene lactones (taraxinic acid β-D-glucopyranosyl ester), and phytosterols (β-sitosterol, cycloartenol) Dandelion Root — Dandelion root is the root material or root extract of Taraxacum officinale, a polychemical botanical preparation containing phenolic acids, flavonoids, sesquiterpene lactones, triterpenes, inulin-type carbohydrates, and other phytochemicals. It is formally classified as a botanical dietary supplement or herbal extract rather than a defined single-molecule oncology drug. Standard abbreviations include DRE for dandelion root extract and T. officinale for the plant species. Current oncology relevance is mainly preclinical, with repeated in-vitro and xenograft signals but no completed convincing human cancer efficacy trial. Primary mechanisms (ranked):
Bioavailability / PK relevance: Dandelion root extract is not a standardized single active agent, so formal human PK is not well established. Oral use is plausible as a botanical preparation, but systemic exposure to the same complex extract composition used in cell culture is unknown. Inulin-rich root material may also act partly through gastrointestinal or microbiome-facing exposure rather than direct plasma-equivalent exposure. In-vitro vs systemic exposure relevance: Many anticancer experiments use crude extract concentrations in the mg/mL range and exposure windows of 24–96 hours. These concentrations should not be assumed to be systemically achievable after oral use. Colorectal and gastrointestinal tumor models may have relatively better luminal-exposure plausibility than distant solid-tumor systemic exposure, but clinical translation remains unproven. Clinical evidence status: Preclinical. Evidence includes cell-line studies, some xenograft studies, and case-report-level human observations. A phase I cancer trial effort was reported as Health Canada-approved/recruiting, but there is no clear completed trial demonstrating cancer efficacy. It should not be treated as an established anticancer therapy. Safety / deployment status: Dandelion is widely marketed as a food/herbal dietary supplement and is generally considered likely safe at food-level intake, but concentrated medicinal doses have less safety evidence. Important constraints include possible allergy in Asteraceae-sensitive individuals, theoretical interactions with antidiabetic, anticoagulant/antiplatelet, lithium, diuretic, and other medications, and uncertainty in pregnancy or breastfeeding. Hormone-sensitive cancer caution is reasonable because some preclinical evidence suggests estrogenic activity and possible stimulation of hormone-sensitive breast cancer models. Dandelion Root Cancer Mechanism Table
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: protein |
| Albumin is a protein found in the blood that plays a crucial role in maintaining various bodily functions, including blood volume, blood pressure, and the transport of hormones, vitamins, and minerals. Associated with improved prognosis in certain types of cancer. May be a marker of improved nutritional status and reduced inflammation in cancer patients. Albumin is the most abundant plasma protein, synthesized by the liver. Biologically, it maintains oncotic pressure, transports hormones/drugs, and buffers redox and metabolic stress. In oncology, serum albumin is a host-state biomarker, not a tumor marker. What Low Albumin Means in Cancer -Hypoalbuminemia reflects a convergence of cancer-relevant processes: -Chronic inflammation (IL-6 suppresses hepatic albumin synthesis) -Catabolism and cachexia -Poor nutritional reserve -Liver synthetic stress -Advanced systemic disease Low albumin is therefore a global severity signal, not a single-pathway readout. |
| 6353- | DRE, | Cisplatin, | Insights Into Protective Mechanisms of Dandelion Leaf Extract Against Cisplatin-Induced Nephrotoxicity in Rats: Role of Inhibitory Effect on Inflammatory and Apoptotic Pathways |
| - | in-vivo, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:222 Target#:690 State#:% Dir#:4
wNotes=0 sortOrder:rid,rpid